Empagliflozin retains benefits in 'True' HFpEF Patients
By : Dr. Prem Aggarwal
By : Dr. Nandita Mohan
Published On 2021-12-03 12:01 GMT | Update On 2021-12-15 06:31 GMT
Advertisement
Empagliflozin provides a wide range of benefits in patients with "true" heart failure and preserved ejection fraction (HFpEF) , meaning an LVEF of 50% or greater, EMPEROR-Preserved investigators report. The main results of the placebo-controlled trial, showed that the sodium-glucose cotransporter 2 (SGLT2) inhibitor lowers the risk of CV death/hospitalization for heart failure in patients with HFpEF.
But some commentators questioned whether EMPEROR-Preserved was truly a trial of HFpEF because it included patients with ejection fractions between 41% and 49%—considered "midrange" or "mildly reduced" in practice guidelines.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.